ArticlemBio2019
Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 78 citations in OpenAlex.
- Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens forAntimicrobial agents and chemotherapy · 2026Article
- Review
- The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease.The Journal of antimicrobial chemotherapy · 2026Article
- Combinations comprising dual β-lactams and a β-lactamase inhibitor achieve optimal synergistic inhibition ofAntimicrobial agents and chemotherapy · 2025Article
- Case report of peritoneal dialysis-associated peritonitis caused byASM case reports · 2025Article
- Article
- Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens forbioRxiv : the preprint server for biology · 2025Article
- The addition of amoxicillin improves the efficacy of the imipenem-avibactam combination againstAntimicrobial agents and chemotherapy · 2025Article
- Novel C5α-substituted carbapenems enhanceAntimicrobial agents and chemotherapy · 2025Article
- In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates ofAntibiotics (Basel, Switzerland) · 2025Article
- Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques.npj antimicrobials and resistance · 2024Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Multidrug-resistantAmerican journal of ophthalmology case reports · 2024Article
- Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection.Nature communications · 2024Article
- Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.The Journal of antimicrobial chemotherapy · 2024Review
- The use of dual β-lactams to restore susceptibility ofJAC-antimicrobial resistance · 2024Article
- Case Commentary: Dual β-lactam as part of regimen to treatAntimicrobial agents and chemotherapy · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
As a consequence of a growing population of immunocompromised individuals, including transplant recipients and cystic fibrosis patients, there has been a dramatic increase in chronic infections caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.